Edition:
United States

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

37.00USD
15 Dec 2017
Change (% chg)

$1.19 (+3.32%)
Prev Close
$35.81
Open
$39.16
Day's High
$39.16
Day's Low
$37.00
Volume
4,460
Avg. Vol
1,436
52-wk High
$64.00
52-wk Low
$17.24

Latest Key Developments (Source: Significant Developments)

Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance
Friday, 17 Nov 2017 01:00am EST 

Nov 17 (Reuters) - CELYAD SA ::ENDED THE QUARTER WITH EUR 40 MILLION IN CASH.CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019.  Full Article

Celyad SA files for mixed shelf offering of up to $250 mln
Thursday, 31 Aug 2017 04:57pm EDT 

Aug 31 (Reuters) - Celyad SA :Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​.  Full Article

Celyad H1 operating loss narrows to 13.7 million euros
Tuesday, 29 Aug 2017 01:00am EDT 

Aug 29 (Reuters) - CELYAD SA ::H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO.H1 NET LOSS EUR 14.4 MILLION VERSUS LOSS OF EUR 16.9 MILLION YEAR AGO.ENDS THE FIRST HALF OF 2017 WITH EUR 69 MILLION IN CASH AND SHORT-TERM DEPOSITS.  Full Article

Celyad announces new agreements with Celdara medical and Dartmouth College
Friday, 4 Aug 2017 01:01am EDT 

Aug 4 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES NEW AGREEMENTS WITH CELDARA MEDICAL AND DARTMOUTH COLLEGE.‍ONGOING CLINICAL TRIAL DEVELOPMENT BOOSTS CELYAD'S CONFIDENCE IN FUTURE OF ITS ONCOLOGY ASSETS​.‍CELYAD TO RECEIVE AN INCREASED SHARE OF FUTURE REVENUES IN EXCHANGE FOR $25M WORTH OF CASH AND CELYAD SHARES​.‍CELYAD HAS AMENDED ITS EXISTING AGREEMENTS WITH CELDARA MEDICAL, LLC AND DARTMOUTH COLLEGE​.‍UNDER AMENDED AGREEMENTS CELYAD WILL RECEIVE AN INCREASED SHARE OF FUTURE REVENUES GENERATED BY THESE ASSETS, INCLUDING REVENUES FROM ITS SUBLICENSEES​.‍IN RETURN, CELYAD WILL PAY CELDARA MEDICAL LLC AND DARTMOUTH COLLEGE AN UPFRONT PAYMENT OF $12.5 MILLION (EUR 10.6 MILLION) AND $12.5 MILLION WORTH OF CELYAD SHARES​.‍SHARES WILL BE PRICED AT EUR 32.35​.  Full Article

BioLife Solutions executes supply agreement with Celyad for CryoStor
Monday, 31 Jul 2017 06:30am EDT 

July 31 (Reuters) - BioLife Solutions Inc :Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers.Biolife Solutions Inc - has executed a long term supply agreement with Celyad.Biolife Solutions Inc - co's CryoStor clinical grade cell freeze media is incorporated into Celyad's manufacturing process.  Full Article

Celyad reports promising early results at 1st dose level of solid arm of THINK trial
Monday, 19 Jun 2017 01:00am EDT 

June 19 (Reuters) - CELYAD SA ::CELYAD REPORTS PROMISING EARLY RESULTS AT FIRST DOSE LEVEL OF THE SOLID ARM OF THE THINK TRIAL.TWO METASTATIC COLORECTAL CANCER PATIENTS REPORTED AS STABLE DISEASE AT 3-MONTH FOLLOW-UP(REMOVES EXTRANEOUS WORDS).NO TOXICITY SIGNALS REPORTED UP TO NOW.  Full Article

Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells
Tuesday, 30 May 2017 01:00am EDT 

May 30 (Reuters) - CELYAD SA ::CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS.  Full Article

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents
Tuesday, 2 May 2017 01:00am EDT 

May 2 (Reuters) - Celyad Sa : :Celyad grants to Novartis <<>> a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents.This license agreement is related to two targets currently under development by Novartis.Under the terms of the agreement Celyad receives an upfront payment and is eligible to receive success based clinical, regulatory and commercial milestone payments.If all success based milestones are achieved, Celyad is eligible to receive payments, including the upfront payment, totalling $96 million.In addition, Celyad will receive single digit royalties based on net sales of the licensed target associated products.Novartis has the option to extend the agreement to additional targets and/or to convert its license into an exclusive license. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.  Full Article

Celyad FY EBIT loss narrows at 25.6 million euros
Thursday, 23 Mar 2017 02:18am EDT 

Celyad SA : FY loss of 23.6 million euros versus loss of 29.1 million euros year ago . FY EBIT loss 25.6 million euros versus loss of 29.7 million euros year ago . FY net sales 8,523 euros versus 3,000 euros year ago . Cash position: 82.6 million euros ($89.1 million) as of December, 31 2016 . Expected 2017 milestones: initiation of THINK trial (USA) in Q1 2017 . Expects initiation of LINK study (EU) in Q3 2017 .Expects initiation of SHRINK study (US/EU) in Q2 2017.  Full Article

Celyad: USPTO rejects new reexamination request against Celyad's US patent for production of allogeneic TCR-deficient CAR-T cells
Thursday, 16 Mar 2017 02:00am EDT 

Celyad Sa : The U.S. Patent and Trademark Office (USPTO) rejects new reexamination request against Celyad's US patent for production of allogeneic TCR-deficient CAR-T cells .Patent remains valid and enforceable.  Full Article

BRIEF-Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance

* CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)